Trials / Completed
CompletedNCT05890950
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
A 28-Day Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Kallyope Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | K-757 and K-833 | Both administered orally |
| DRUG | Matching placebo to K-757 and K-833 | Both administered orally |
Timeline
- Start date
- 2023-03-13
- Primary completion
- 2023-07-12
- Completion
- 2023-07-12
- First posted
- 2023-06-06
- Last updated
- 2023-10-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05890950. Inclusion in this directory is not an endorsement.